In silico – the future of antibody development
Posted onLearn more about how in silico technology accelerates antibody design and development, which reduces costs.
News
Fusion Antibodies form strategic collaboration with E2DG to provide end-to-end service for oncology drug discovery companies.
Posted onFusion Antibodies and E2DG, a drug development group, are pleased to announce a strategic collaboration.
New technology for Affinity Maturation
Posted onFusion Antibodies are working with a number of clients on pilot projects for their latest technology – RAMP™ – Rational Affinity Maturation Platform. RAMP™ was launched at the end of 2018 and clients have been coming on board to benefit from the innovative in silico approach to Affinity Maturation, particularly for time sensitive projects. The […]
De-risking antibody development
Posted onWhy investing in pre-clinical activity is crucial to maximise the chance of success in clinical trials.
Fusion Antibodies are CIR approved
Posted onFusion Antibodies has been granted approval to participate in the Crédit Impôt Recherche (CIR) scheme, meaning our French clients can enjoy a significant tax break by partnering with us for pre-clinical antibody research.
Fusion Antibodies celebrates Antibody Humanization Milestone
Posted onFusion Antibodies, a world leading CRO, has today announced that they have successfully completed their 150th Antibody Humanization project as part of their Antibody Engineering offering